Home » Biota Acquires Assets from Prolysis and MaxThera for Roughly $11.5M
Biota Acquires Assets from Prolysis and MaxThera for Roughly $11.5M
Australian anti-infectives company Biota reported separate agreements to purchase key assets and drug development programs from Prolysis and MaxThera for
a total consideration of $11.53 million in cash and shares.
Genetic Engineering & Biotechnology News
Genetic Engineering & Biotechnology News
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May